FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055081569> ?p ?o ?g. }

• W2055081569 abstract "Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated with JIA. Major risk factors for development of uveitis in JIA are oligoarticular pattern of arthritis, an age at onset of arthritis of less than seven years of age, and antinuclear antibody positivity. In the initial stages of mild to moderate inflammation the uveitis is asymptomatic. This has led to current practice of screening all children with JIA for uveitis. Approximately 12% to 38% of patients with JIA develop uveitis in seven years following onset of arthritis. In 30% to 50% of children with JIA-associated uveitis structural complications are present at diagnosis. Furthermore about 50% to 75% of those with severe uveitis will eventually develop visual impairment secondary to ocular complications such as cataract and glaucoma. Defining the severity of inflammation and structural complications in uveitis patients is now possible following Standardised Uveitis Nomenclature (SUN) guidelines, and modified to incorporate the consensus of end point and outcome criteria into the design of randomised trials. Despite current screening and therapeutic options (pre-biologics) 10% to 15% of children with JIA-associated uveitis may develop bilateral visual impairment and certified legally blind. To date, there remains no controlled trial evidence of benefits of biologic therapy. This study will randomise 154 patients aged 2 to 18 years with active JIA-associated uveitis (despite methotrexate (MTX) treatment for at least 12 weeks). All participants will be treated for 18 months, with follow up of 3 years from randomisation (continuing on MTX throughout). All participants will receive a stable dose of MTX and in addition either adalimumab (20 mg/0.8 ml for patients <30 kg or 40 mg/0.8 ml for patients weighing 30 kg or more, subcutaneous (s/c) injection every 2 weeks based on body weight), or placebo (0.8 ml as appropriate according to body weight) s/c injection every 2 weeks. This is the first randomised controlled trial that will assess the clinical effectiveness, safety and cost effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis. ISRCTN10065623" @default.
• W2055081569 created "2016-06-24" @default.
• W2055081569 creator A5005129884 @default.
• W2055081569 creator A5015700716 @default.
• W2055081569 creator A5029898835 @default.
• W2055081569 creator A5041204910 @default.
• W2055081569 creator A5041240121 @default.
• W2055081569 creator A5049640228 @default.
• W2055081569 creator A5053573851 @default.
• W2055081569 creator A5060800328 @default.
• W2055081569 creator A5060906323 @default.
• W2055081569 creator A5063923011 @default.
• W2055081569 creator A5070376982 @default.
• W2055081569 creator A5076377634 @default.
• W2055081569 date "2014-01-09" @default.
• W2055081569 modified "2023-10-10" @default.
• W2055081569 title "A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)" @default.
• W2055081569 cites W1749702789 @default.
• W2055081569 cites W1967213626 @default.
• W2055081569 cites W1969936299 @default.
• W2055081569 cites W1970299052 @default.
• W2055081569 cites W1973730472 @default.
• W2055081569 cites W1977063092 @default.
• W2055081569 cites W1979532130 @default.
• W2055081569 cites W1986380854 @default.
• W2055081569 cites W1986561345 @default.
• W2055081569 cites W1987316389 @default.
• W2055081569 cites W1987733166 @default.
• W2055081569 cites W1992051074 @default.
• W2055081569 cites W1996117162 @default.
• W2055081569 cites W1997485798 @default.
• W2055081569 cites W2003525300 @default.
• W2055081569 cites W2023774600 @default.
• W2055081569 cites W2024898666 @default.
• W2055081569 cites W2026629764 @default.
• W2055081569 cites W2026718163 @default.
• W2055081569 cites W2027090790 @default.
• W2055081569 cites W2036644487 @default.
• W2055081569 cites W2044668285 @default.
• W2055081569 cites W2046628605 @default.
• W2055081569 cites W2050695305 @default.
• W2055081569 cites W2052365009 @default.
• W2055081569 cites W2064325706 @default.
• W2055081569 cites W2064877272 @default.
• W2055081569 cites W2071008401 @default.
• W2055081569 cites W2073127781 @default.
• W2055081569 cites W2073700972 @default.
• W2055081569 cites W2075966345 @default.
• W2055081569 cites W2077177293 @default.
• W2055081569 cites W2081575995 @default.
• W2055081569 cites W2090571666 @default.
• W2055081569 cites W2090980889 @default.
• W2055081569 cites W2093379143 @default.
• W2055081569 cites W2098495975 @default.
• W2055081569 cites W2098679112 @default.
• W2055081569 cites W2102631597 @default.
• W2055081569 cites W2115631220 @default.
• W2055081569 cites W2124151296 @default.
• W2055081569 cites W2133038175 @default.
• W2055081569 cites W2135325634 @default.
• W2055081569 cites W2139499737 @default.
• W2055081569 cites W2143999806 @default.
• W2055081569 cites W2147714125 @default.
• W2055081569 cites W2154980334 @default.
• W2055081569 cites W2157110439 @default.
• W2055081569 cites W2158722755 @default.
• W2055081569 doi "https://doi.org/10.1186/1745-6215-15-14" @default.
• W2055081569 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3892031" @default.
• W2055081569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24405833" @default.
• W2055081569 hasPublicationYear "2014" @default.
• W2055081569 type Work @default.
• W2055081569 sameAs 2055081569 @default.
• W2055081569 citedByCount "85" @default.
• W2055081569 countsByYear W20550815692014 @default.
• W2055081569 countsByYear W20550815692015 @default.
• W2055081569 countsByYear W20550815692016 @default.
• W2055081569 countsByYear W20550815692017 @default.
• W2055081569 countsByYear W20550815692018 @default.
• W2055081569 countsByYear W20550815692019 @default.
• W2055081569 countsByYear W20550815692020 @default.
• W2055081569 countsByYear W20550815692021 @default.
• W2055081569 countsByYear W20550815692022 @default.
• W2055081569 countsByYear W20550815692023 @default.
• W2055081569 crossrefType "journal-article" @default.
• W2055081569 hasAuthorship W2055081569A5005129884 @default.
• W2055081569 hasAuthorship W2055081569A5015700716 @default.
• W2055081569 hasAuthorship W2055081569A5029898835 @default.
• W2055081569 hasAuthorship W2055081569A5041204910 @default.
• W2055081569 hasAuthorship W2055081569A5041240121 @default.
• W2055081569 hasAuthorship W2055081569A5049640228 @default.
• W2055081569 hasAuthorship W2055081569A5053573851 @default.
• W2055081569 hasAuthorship W2055081569A5060800328 @default.
• W2055081569 hasAuthorship W2055081569A5060906323 @default.
• W2055081569 hasAuthorship W2055081569A5063923011 @default.
• W2055081569 hasAuthorship W2055081569A5070376982 @default.
• W2055081569 hasAuthorship W2055081569A5076377634 @default.
• W2055081569 hasBestOaLocation W20550815691 @default.
• W2055081569 hasConcept C126322002 @default.
• W2055081569 hasConcept C141071460 @default.
• W2055081569 hasConcept C187212893 @default.

• next